Wirkstoffe & Arzneimittelsicherheit

Nebenwirkungen · Elzonris

ELZONRIS 1 mg/mL concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 8–9

HOS-292268 · Präparat HOS-287636

8 MedDRA System Frequency of CTCAE grade 3 and Frequency of all CTCAE grades Organ Class above Vision blurred Uncommon Conjunctival haemorrhage Ocular hyperaemia Vitreous floaters Cardiac Disorders Common Uncommon Pericardial effusion Ventricular fibrillation Tachycardia Pericardial effusion Sinus tachycardia Sinus tachycardia Uncommon Myocardial infarction Ventricular fibrillation Supraventricular extrasystoles Atrial fibrillation Bradycardia Myocardial infarction Vascular disorders Very Common Common Capillary leak syndrome Capillary leak syndrome Hypotensiona Hypotension Common Flushing Uncommon Hypertension Haematoma Respiratory, thoracic Common Common and mediastinal Hypoxia Hypoxia disorders Pulmonary oedema Pulmonary oedema Dyspnoea Uncommon Epistaxis Respiratory failure Pleural effusion Dyspnoea Cough Uncommon Respiratory failure Wheezing Oropharyngeal pain Tachypnoea Gastrointestinal Very Common Uncommon Disorders Nausea Nausea Vomiting Common Dysphagia Diarrhoea Stomatitis Dyspepsia Dry mouth Constipation Uncommon Abdominal distension Abdominal pain Gingival bleeding Tongue blistering Tongue haematoma Hepatobiliary Common None disorders Hyperbilirubinemia Skin and Common Uncommon subcutaneous tissue Pruritus Angioedema disorders Rashb Rash Hyperhidrosis Petechiae Uncommon Angioedema

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.